



February 14, 2007

## **Nektar Sets Announcement Date and Conference Call for Year End and Fourth Quarter 2006**

SAN CARLOS, Calif., Feb 14, 2007 (BUSINESS WIRE) -- Nektar Therapeutics (Nasdaq:NKTR) will announce its financial results for year end and fourth quarter 2006 on Wednesday, February 28, 2007. On that day, Mr. Howard Robin, president and chief executive officer, will host a conference call for analysts and investors beginning at 2:00 p.m. Pacific Time, to discuss further the Company's performance.

Investors can access a live audio-only webcast through a link that is posted on the Investor Relations section of Nektar's website at <http://www.nektar.com>. The web broadcast of the conference call will be available for replay through March 14, 2007.

Analysts and investors can also access the conference call live via telephone by dialing (800) 640-9765 (U.S.); (847) 413-4837 (international). The passcode is 17025300 and the host is Mr. Howard Robin. An audio replay will be available shortly following the call through March 14, 2007 and can be accessed by dialing (877) 213-9653 (U.S.); or (630) 652-3041 (international) with a passcode of 17025300. In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

Nektar Therapeutics is a biopharmaceutical company with a mission to develop and enable differentiated therapeutics with its industry-leading technologies, expertise and manufacturing capabilities. Nektar technology and know-how have enabled nine approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its technologies and expertise to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

SOURCE: Nektar Therapeutics

Nektar Therapeutics  
Joyce Strand, 650-631-3138

Copyright Business Wire 2007

News Provided by COMTEX